AC Immune starts enrolling patients for next Phase 2 trial of anti-Tau
Category: #health  By Nikita Chaurasia  Date: 2019-02-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

AC Immune starts enrolling patients for next Phase 2 trial of anti-Tau
  • The antibody, called as MTAU9937A, RO7105705, is also being assessed by Genentech in a different Phase 2 trial
  • Anti-Tau monoclonal antibody was detected and improved under the collaboration between AC Immune and Genentech

The Switzerland-based clinical-stage biopharmaceutical company AC Immune has reportedly declared that Genentech has commenced enrollment of patients for a second Phase 2 trial for an anti-Tau monoclonal antibody, called as MTAU9937A, RO7105705, developed to treat moderate Alzheimer’s disease.

As per trusted sources, the same antibody is also being assessed by Genentech in a different Phase 2 trial to measure it safety and efficacy in patients with prodromal-to-mild Alzheimer's disease.

Chief Executive Officer of AC Immune, Professor Andrea Pfeifer was reportedly quoted saying that the company is highly encouraged owing to the fact the Genentech is expanding its clinical assessment of AC Immune’s anti-Tau antibody. The interest to target Tau was recently shown by the company’s newest collaboration with Eli Lilly which was formed in early January to develop small molecule Tau MorphomerTM to treat Alzheimer’s, Pfeifer further added.

Reportedly, these projects demonstrate the scientific leadership of AC Immune in the field and are a significant part of its broad portfolio of three product candidates in Phase 2 clinical testing, an increasingly visible focus on early projects targeting neuro-inflammation and neuro-orphan indications, and additional diagnostics in clinical development.

According to a press release by AC Immune, the development of the monoclonal antibody is an important aspect of the partnership the company formed with Genentech in the year 2012 to market the monoclonal humanized antibodies against Tau protein. Reportedly, the monoclonal antibody was detected and improved under the collaboration between AC Immune and Genentech.

For the record, Tau pathology spreads with a distinctive spatiotemporal pattern in the brain, coinciding with both disease progression and clinical symptoms in Alzheimer’s disease.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

GSK, Zymeworks expand partnership for bispecific antibody development
GSK, Zymeworks expand partnership for bispecific antibody development
By Nikita Chaurasia

GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases Zymeworks Inc, a clinical-stage biopharmaceutical company, has recently announced that GSK has extended its 2016 licensing ...

Vertex, Kymera join forces for developing protein degradation drugs
Vertex, Kymera join forces for developing protein degradation drugs
By Nikita Chaurasia

Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company Kymera Therapeutics and Vertex Pharmaceuticals Incorporated (VRTX) have reportedly announced that they are entering into a four-year rese...

Amazon plans job cuts as it deploys machines to pack orders
Amazon plans job cuts as it deploys machines to pack orders
By Nikita Chaurasia

Amazon is well known for its drive to automate as many segments of its business as possible. The American multinational technology company Amazon Inc. is reportedly planning to deploy machines to automate boxing up customer orders. The company has i...